DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer November 7, 2017 • 4:05 PM EST
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer October 31, 2017 • 5:30 AM EDT
DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer October 3, 2017 • 5:30 AM EDT
DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer September 27, 2017 • 5:30 AM EDT
DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market September 22, 2017 • 2:20 PM EDT
DelMar Pharmaceuticals Announces $10 Million Registered Direct Offering Priced At-The-Market September 20, 2017 • 3:31 PM EDT
DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083 September 20, 2017 • 5:30 AM EDT
DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer September 18, 2017 • 8:00 AM EDT
DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme September 11, 2017 • 4:00 AM EDT